Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
  • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
  • C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
  • C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
  • C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
  • C07C29/80—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment by distillation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
  • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
  • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
  • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
  • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

• the present invention relates to the fields of pharmaceutical chemistry and synthetic organic chemistry.
• (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3- dihydroxypropyl)cyclopropane-l -sulfonamide are known to possess inhibitory properties against MEK enzymes and are of therapeutic value (see US published patent application US 2008/0058340 Al). Described herein are methods for their preparation.
• R 1 is H or an alcohol protecting group
• R 2 is H or an alcohol protecting group
• R 1 and R 2 together with the carbon atoms to which they are attached form a cyclic 1,2-diol protecting group.
• the compound of formula (I-a) is (R)- ⁇ -(3,4-difluoro-2-(2-fiuoro-4- iodophenylamino)-6-methoxyphenyl)- 1 -((2,2-dimethyl-l ⁇ -dioxolan ⁇ -ylJmethyOcyclopropane- 1 -sulfonamide:
• the compound of formula (II-a) is (R)-1-((2,2-dimethyl-1,3-dioxolan-4- yl)methyl)cyclopropane- 1 -sulfonyl chloride:
• R 1 is H or an alcohol protecting group
• R 2 is H or an alcohol protecting group
• R 1 and R 2 together with the carbon atoms to which they are attached form a cyclic 1,2-diol protecting group.
• the compound of formula (I-b) is (S)- ⁇ -(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonamide:
• the compound of formula (II-b) is (S)-1-((2,2-dimethyl-1,3-dioxolan-4- yl)methyl)cyclopropane-1-sulfonyl chloride:
• R 1 is H or an alcohol protecting group
• R 2 is H or an alcohol protecting group
• R 1 and R 2 together with the carbon atoms to which they are attached form a cyclic 1,2-diol protecting group.
• the compound of formula (I-a) is (R)-N-(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonamide:
• R 1 is H or an alcohol protecting group
• R 2 is H or an alcohol protecting group
• R 1 and R 2 together with the carbon atoms to which they are attached form a cyclic 1,2-diol protecting group.
• the compound of formula (I-b) is (S)-N-(3,4-difiuoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonamide:
• R 1 is H and R 2 is an alcohol protecting group.
• R 2 is H and R 1 is an alcohol protecting group. In further or additional embodiments, both R 1 and R 2 are alcohol protecting groups. In further or additional embodiments, both R 1 and R 2 are hydrogen. In further or additional embodiments, the protecting groups are the same. In further or additional embodiments, the protecting groups are different. In further or additional embodiments, R 1 and R 2 together with the carbon atoms to which they are attached form a cyclic 1,2-diol protecting group. In further or additional embodiments, the cyclic 1,2-diol protecting group is a 5-membered cyclic 1,2-diol protecting group. In further or additional embodiments, the cyclic 1,2-diol protecting group is 2,2-dimethyl-1,3-dioxolan-4-yl.
• the compounds (R)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1- sulfonyl chloride and (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonyl chloride are provided:
• the compounds (R)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)prop-1-ene-2-sulfonyl chloride and (S)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)prop-1-ene-2-sulfonyl chloride are provided:
• the compounds sodium (R)-1-((2,2-dimethyl-1,3-dioxolan-4- yl)methyl)cyclopropane- 1 -sulfonate and sodium (S)- 1 -((2,2-dimethyl- 1 ,3-dioxolan-4-yl)methyl)cyclopropane- 1 - sulfonate are provided:
• the compounds (R)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropanethiol and (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropanethiol are provided: [0018] In some embodiments, the compounds 1,2-bis(l-(((R)-2,2-dimethyl-1,3-dioxolan-4- yl)methyl)cyclopropyl)disulfane and 1,2-bis(l-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropyl)disulfane are provided:
• Figure 1 represents three HPLC traces of N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6- methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide, wherein the top trace l(a) is the HPLC trace of the crude material, co-injected with an authentic sample of the (-) enantiomer (obtained via chiral separation of the racemic mixture of both isomers); the middle trace l(b) is the HPLC trace of the crude material; and the lower trace l(c) is the HPLC trace of the crude material, co-injected with an authentic sample of the (+) enantiomer (obtained via chiral separation of the racemic mixture of both isomers).
• Figure 2 represents the 1 H NMR spectrum of sodium (S)-1-((2,2-dimethyl-1,3-dioxolan-4- yl)methyl)cyclopropane-l -sulfonate in CD 3 OD.
• Figure 3 represents the 13 C NMR spectrum of sodium (S)-1-((2,2-dimethyl-1,3-dioxolan-4- yl)methyl)cyclopropane-l -sulfonate in CD 3 OD.
• the compounds used in the reactions described herein may be made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature.
• “Commercially available chemicals” may be obtained from standard commercial sources including Acros Organics (Pittsburgh PA), Aldrich Chemical (Milwaukee WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park UK), Avocado Research (Lancashire U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.),Chemservice Inc. (West Chester PA), Crescent Chemical Co. (Hauppauge NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester NY), Fisher Scientific Co. (Pittsburgh PA), Fisons Chemicals (Leicestershire UK), Frontier Scientific (Logan UT), ICN
• Schemes 2a, 3a, 4a, 5a and 6a show synthetic routes by which (R)-N-(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide could be prepared, and are discussed below.
• Schemes 2b, 3b, 4b, 5b and 6b show synthetic routes by which (S)-N-(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide could be prepared, and are discussed below.
• Method B, Route I A cyclopropyl group is introduced across the alkene of diol-protected 4-iodopent-4- ene-1,2-diol, to form the protected 3-(l-iodocyclopropyl)propane-1,2-diol derivative, which is then sulfonylated.
• Method B, Route II In a slightly different approach to route A above, the cyclopropanation reaction may be affected after coupling with the diaryl amine. Diol protected 4-iodopent-4-ene-1,2-diol is converted to the sulfonyl chloride and then coupled with 5,6-difluoro-N 1 -(2-fluoro-4-iodophenyl)-3-methoxybenzene-1,2-diamine.
• glycidol is available commercially as the (R) enantiomer, the (S) enantiomer or the (R/S)-(+/-)- mixture.
• the alcohol can be protected, for example by reaction with 'butyldimethylsilyl chloride, or other suitable protecting group.
• the TBS protected glycidol is available commercially as the (R) enantiomer, the (S) enantiomer or the (R/S)-(+/-)-racemic mixture.
• Method B Diol protected l-(2,3-dihydroxypropyl)cyclopropane-1-sulfonyl chloride: In some embodiments, the diol protected l-(2,3-dihydroxypropyl)cyclopropane-1-sulfonyl chloride intermediate is used.
• 1,2 Diol protecting groups are well known in the art such as, though not limited to 1,3-dioxolane, 2-methyl-1,3- dioxolane, 2,2-dimethyl-1,3-dioxolane, 2-'butyl- 1,3-dioxolane, 2-phenyl-1,3-dioxolane, 1,4- dioxaspiro[4.5]decane, di-para -methoxybenzyloxymethyl ether, di-'butyldimethylsilyl ether, and the like:
• Conversion of the sulfonate to the sulfonyl chloride provides the sulfonyl chloride derivative, l-(2-hydroxy-3-protected- hydoxypropyl)cyclopropane-1-sulfonyl chloride, which is then coupled with 5,6-difluoro-N'-(2-fluoro-4- iodophenyl)-3-methoxybenzene-1,2-diamine.
• Oxidative cleavage eg Ozonolysis or Lemieux- Johnson oxidation
• amine protected l-allyl-N-(3,4- difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)cyclopropane- 1 -sulfonamide, followed by conversion to the ⁇ -hydroxyketone, chiral reduction of the ketone (eg Corey CBS reduction) and removal of protecting groups, as required yields the desired chiral products.
• Scheme 7a shows a synthetic route for the preparation (R)-N-(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
• Scheme 7b shows a synthetic route for the preparation (S)-N-(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-l -sulfonamide.
• Methods for the preparation of the diol-protected l-(2,3-dihydroxypropyl)cyclopropane-1-sulfonyl chloride include:
• glycidol is available commercially as the (R) enantiomer, the (S) enantiomer or the (R/S)-(+/-)- mixture.
• the alcohol can be protected, for example by reaction with 'butyldimethylsilyl chloride (TBS-Cl), or other suitable protecting group.
• TBS protected glycidol is available commercially as the (R) enantiomer, the (S) enantiomer or the (R/S)-(+/-)-racemic mixture.
• a cyclopropyl group is introduced across the alkene of diol-protected 4-iodopent-4-ene-1,2-diol, to form the protected 3-(l-iodocyclopropyl)propane-1,2- diol derivative, which is then sulfonylated.
• the 1,2-bis(l-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropyl) disulfane intermediate can be prepared either directly by reacting 1 ,2-dicyclopropyldisulfane with 4-(bromomethyl)-2,2-dimethyl-1,3-dioxolane (route ii-a), or by coupling 1,2-dicyclopropyldisulfane with ter/-butyldimethyl(oxiran-2-ylmethoxy)silane, followed by removal of the TBS protecting group and protection of the resulting diol (route ii-b).
• the 1,2-bis(l-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropyl) disulfane can be directly converted to the sulfonyl chloride (route ii-c), or via the sulfonate salt, which is then converted to the chloride (route ii-d).
• the disulfane can be reduced to the sulfide, which is then oxidized to the sulfonate and converted to the sulfonyl chloride (route ii-e):
• Protecting groups are used to block some or all alcohol and/or amine functional groups to prevent them from participating in chemical reactions until the protective group is removed. In some embodiments, wherein more than one protective group is required, each protective group is removable by a different means. In other embodiments, wherein more than one protective group is required, multiple protective groups are removable by the same means. In some embodiments, wherein more than one protective group is required, a single protecting group maybe used to protect multiple functionalities (eg a cyclic group). Protective groups can be removed by treatment with acid, base, a nucleophile, hydrogenolysis or by exposure to UV light or a combination thereof.
• groups such as trityl, dimethoxytrityl, acetal and f-butyldimethylsilyl are acid labile; groups such as methyl, ethyl and acetyl are base labile and groups such as /-butyl carbamate and benzyl are hydrolytically removed.
• Another form of protecting group is a resin to which a compound or intermediate may be attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.
• intermediates comprising a protected alcohol are required.
• Alcohol protecting groups are well known to those of skill in the art of organic chemistry, and are well described in the literature (see for example "Protecting Groups in Organic Synthesis” by Greene & Wuts, 3 rd edition, 1999, John Wiley and Sons, Inc., New York, NY; Chapter 2 - “Protection for the Hydroxyl Group, Including 1,2-and1,3-Diols").
• alcohol protecting groups include, but are not limited to substituted methyl ethers, such as methoxymethyl, benzyloxymethyl, p -methoxybenzyloxymethyl, t-butoxymethyl, tetrahydropyranyl, methoxycyclohexyl, methoxytetrahydropyranyl, tetrahydrofuranyl; substituted ethyl ethers, such as ethoxyethyl, /-butyl, allyl, propargyl; substituted benzyl ethers such as p-methoxybenzyl, picolyl, diphenylmethyl, triphenylmethyl;
• silylethers such as trimethylsilyl, triisopropylsilyl, t-butyldimethylsilyl, tribenzylsilyl, triphenylsilyl; esters, carbonates, sulfonates and the like.
• 1,2-Diol protecting groups are well known to those of skill in the art of organic chemistry. Examples of 1,2-diol protecting groups include, but are not limited to 1,3-dioxolane, 2-methyl-1,3-dioxolane, 2,2-dimethyl-1,3-dioxolane, 2-'butyl-1,3- dioxolane, 2-phenyl-1,3-dioxolane, 1,4-dioxaspiro[4.5]decane, di-para-methoxybenzyloxymethyl ether, di- 'butyldimethylsilyl ether, and the like:
• tert-BuLi (12.4 ml, 1.7M, 21.1 mmol) was added to a solution of TMS-acetylene (2.12 g, 21.7 mmol) in THF (40 ml) at -78°C and the reaction mixture was stirred for an additional 30 min.
• (R)-tert- butyldimethyl(oxiran-2-ylmethoxy)silane (2 g, 10.6 mmol) and BF 3 -EtO 2 (3g, 21.1 mmol) were added and stirred at -78°C for 4.5 hours.
• reaction was then quenched by addition of aqueous ammonium chloride solution and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried (MgSO 4 ) and concentrated under reduced pressure to afford the desired material in a quantitative yield. The material was used in the next step with no further purification.
• Trifluoroacetic acid (TFA; 281 mg, 2.47 mmol) was added to a solution of diethyl zinc (ZnEt 2 , 2.5 mL, 2.5M in hexane) in DCE (1 mL) at 0oC and stirred for 35 mins.
• Diiodomethane (CH 2 I 2 , 66 mg, 2.5 mmol) was then added at OoC, and the mixture stirred for an additional 20 min.
• step D A solution of (R)-5-(2-iodoallyl)- 2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane (step D; 188 mg, 0.41 mmol) in DCE (2ml) was added and the reaction stirred at room temperature overnight. The reaction was then quenched by addition of a mixture of methanol (5 mL) and brine (0.5 mL). After stirring for an additional hour, the mixture was concentrated under reduced pressure. The crude material was extracted with aq.NH 4 Cl/CHCl 3 and the organic layer washed with brine, dried (MgSO 4 ) and concentrated under reduced pressure.
• Aqueous HCl solution (0.3 mL, IN) was added to a solution of (R)-5-((l-iodocyclopropyl)methyl)- 2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane (step E, 281 mg, 0.598 mmol) in THF (2 mL) at 0oC.
• the mixture was slowly warmed at room temperature and stirred for 24 hours.
• the reaction was quenched by addition of aqueous NaHCO 3 solution and extracted with ethyl acetate.
• tert-Buty ⁇ lithium (0.2 mL, 0.34 mmol, 1.7M) was added to a solution of (R)-4-((l- iodocyclopropyl)methyl)-2,2-dimethyl-1,3-dioxolane (step G, 45 mg, 0.16 mmol) in ether (1 mL) at -78°C and the mixture stirred at -78°C for 30 mins. A solution of thionyl chloride (26 ⁇ L) in ether (0.5 mL) was then added. The resulting orange solution was warmed to room temperature and concentrated under reduced pressure.
• the compound was analyzed by normal-phase HPLC using a CHIRALPAK AD-H column (20 x 250 mm) at room temperature, using a mobile phase consisting hexane and 2-propanol (80:20) at 12 mL/min. The detection was carried out at 254 nm. The retention time was determined to be 22 min corresponding to the retention time of (+)N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl) cyclopropane- 1 -sulfonamide.
• Figure l(a) is the HPLC trace of the crude material, co-injected with an authentic sample of the (-) enantiomer
• Figure l(b) is the HPLC trace of the crude material
• Figure l(c) is the HPLC trace of the crude material, co-injected with an authentic sample of the (+) enantiomer
• tert-Butyl lithium (2eq) is added to a solution of TMS-acetylene (2eq) in THF at -78°C and the reaction mixture stirred for an additional 30 min.
• (S)-tert-butyldimethyl(oxiran-2-ylmethoxy)silane (leq) and BF 3 -EtO 2 (2eq) are added and stirred at -78°C for 4.5 hours.
• the reaction is quenched by addition of aqueous ammonium chloride solution and extracted with ethyl acetate (3x).
• 9-Iodo-9-borabicyclo[3.3.1]nonane (9-I-BBN) is added dropwise to a solution (S)-1-(tert- butyldimethylsilyloxy) pent-4-yn-2-ol in dichloromethane at 0oC and the reaction stirred at 0oC for 4 hours. Glacial acetic acid is added and the mixture was stirred for an additional hour at 0oC.
• STEP D (S)-5-(2-iodoallyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane
• STEP E (S)-5-((l-iodocyclopropyl)methyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane
• Trifluoroacetic acid (8eq) is added to a solution of diethyl zinc (16 eq) in DCE at 0oC and stirred for 35 mins.
• Diiodomethane (8 eq) is added at OoC, and the mixture stirred for an additional 20 min.
• a solution of (S)-5- (2-iodoallyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane (1 eq) in DCE is added and the reaction stirred at room temperature overnight. The reaction is quenched by addition of a mixture of methanol and brine. After stirring for an additional hour, the mixture is concentrated under reduced pressure.
• Aqueous HCl solution is added to a solution of (S)-5-((l-iodocyclopropyl)methyl)-2,2,3,3,8,8,9,9- octamethyl-4,7-dioxa-3,8-disiladecane in THF at 0oC.
• the mixture is slowly warmed to room temperature and stirred for 24 hours.
• the reaction is quenched by addition of aqueous NaHCO 3 solution, extracted with ethyl acetate, and the combined organic layers washed with brine, dried (MgSO 4 ) and concentrated under reduced pressure to provide (S)-3-(l-iodocyclopropyl)propane-1,2-diol (0.598 mmol).
• tert-Butyl lithium (2eq) is added to a solution of (S)-4-((l-iodocyclopropyl)methyl)-2,2-dimethyl-1,3- dioxolane (leq) in ether at -78°C and the mixture stirred at -78°C for 30 mins.
• a solution of thionyl chloride in ether is added, the mixture warmed to room temperature and concentrated under reduced pressure. The residue is dissolved in chloroform, filtered and dried under reduced pressure.
• tert-Butyl lithium is added to a solution of (R)-4-(2-iodoallyl)-2,2-dimethyl-l ,3-dioxolane in ether at - 78°C and the mixture stirred at -78°C for 30 mins.
• a solution of thionyl chlo ⁇ de in ether is then added, the mixture warmed to room temperature and concentrated under reduced pressure. The residue is dissolved in chloroform, filtered and dried under reduced pressure.
• Potassium carbonate is added to a solution of (S)-1-(ter/-butyldimethylsilyloxy)-5-(trimethylsilyl)pent-4- yn-2-ol in methanol and the mixture stirred at room temperature for 8 hours. The solvent is removed under reduced pressure, aqueous ammonium chloride solution added, and the mixture extracted with ethyl acetate (3x). The combined organic layers are washed with brine, dried (MgSO,*), concentrated under reduced pressure and purified by flash chromatography (biotage; ethyl acetate / hexane gradient).
• 9- Iodo-9-borabicyclo[3.3. l]nonane (9-I-BBN) is added dropwise to a solution (S)-1-(tert- butyldimethylsilyloxy) pent-4-yn-2-ol in dichloromethane at OoC and the reaction stirred at 0oC for 4 hours. Glacial acetic acid is added and the mixture stirred for an additional hour at OoC. An aqueous mixture of Na 2 CO 3 /Na 2 S 2 O 3 (1:1) is added and the resulting solution extracted with ethyl acetate (3x). The combined organic layers are dried (MgSO 4 ) and concentrated under reduced pressure.
• tert-Butyl lithium is added to a solution of (S)-4-(2-iodoallyl)-2,2-dimethyl-1,3-dioxolane in ether at - 78°C and the mixture stirred at -78°C for 30 mins.
• a solution of thionyl chloride in ether is then added, the mixture warmed to room temperature and concentrated under reduced pressure. The residue is dissolved in chloroform, filtered and dried under reduced pressure.
• EXAMPLE 5 fR')-N-(3.4-Difluoro-2-f2-fluoro-4-iodophenvlamino')-6-methoxvphenvlV3-(2.2-dimethvl- 1 ,3-dioxolan-4-yl)prop-l -ene-2-sulfonamide
• EXAMPLE_6 (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-3-(2,2-dimethyl- 1,3-dioxolan-4-yl)prop-1-ene-2-sulfonamide
• a solution 9-bromo-9-borabicyclo[3.3. l]nonane (9-Br-BBN) in dichloromethane is added dropwise to a solution of (S)-I -(tert-butyldimethylsilyloxy)pent-4-yn-2-ol in dichloromethane at 0oC, and the mixture stirred at 0oC for 4 hours. Glacial acetic acid is added and stirring continued at 0oC for an additional 1 hour. Ethanolamine is added and the mixture allowed to warm to room temperature.
• N-Chloro succinimide (NCS, 1 eq) is added to a mixture of 2 M HCl (0.6 mL/mmol) and acetonitrile (3.4 mL/mmol) and cooled to 10 oC.
• EXAMPLE 8 1 ,2-Bis(l -(((S)-2,2-dimethyl- 1 ,3-dioxolan-4-yl)methyl)cyclopropyl)disulfane
• STEP A 1,2-Bis(l-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropyl)disulfane
• STEP B (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonyl chloride
• N-Chloro succinimide (NCS, 1 eq) is added to a mixture of 2 M HCl (0.6 mL/mmol) and acetonitrile (3.4 mL/mmol) and cooled to 10 oC.
• STEP B (S)-1-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonyl chloride
• EXAMPLE 11 (R)-I -((2,2-Dimethyl- 1 , 3 -dioxolan ⁇ -yOmethyOcyclopropane- 1 -sulfonyl chloride STEP A: (R)-1-((2,2-Dimethyl-l ,3-dioxolan-4-yl)methyl)cyclopropanethiol
• EXAMPLE 12 (S)- 1 -((2,2-Dimethyl- 1 ,3-dioxolan-4-yl)methyl)cyclopropane- 1 -sulfonyl chloride
• Figure 2 shows the 1 H NMR spectrum of sodium (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1- sulfonate in CD 3 OD.
• Figure 3 shows the 13 C NMR spectrum of sodium (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1- sulfonate in CD 3 OD.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Indole Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Priority Applications (21)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=42830488

Family Applications (1)

Country Status (31)

Cited By (3)

Families Citing this family (1)

Citations (2)

Family Cites Families (5)

• 2010
  • 2010-07-09 TW TW099122740A patent/TWI524890B/zh not_active IP Right Cessation
  • 2010-07-10 MY MYPI2012000099A patent/MY160421A/en unknown
  • 2010-07-10 CU CUP2012000014A patent/CU24113B1/es active IP Right Grant
  • 2010-07-10 EP EP10734043.2A patent/EP2462111B1/en active Active
  • 2010-07-10 CA CA2990097A patent/CA2990097A1/en not_active Abandoned
  • 2010-07-10 BR BR112012001592A patent/BR112012001592A2/pt not_active Application Discontinuation
  • 2010-07-10 IN IN696DEN2012 patent/IN2012DN00696A/en unknown
  • 2010-07-10 JP JP2012520927A patent/JP5776115B2/ja not_active Expired - Fee Related
  • 2010-07-10 NZ NZ597738A patent/NZ597738A/en not_active IP Right Cessation
  • 2010-07-10 US US13/386,519 patent/US8513443B2/en not_active Expired - Fee Related
  • 2010-07-10 EA EA201200175A patent/EA023623B1/ru not_active IP Right Cessation
  • 2010-07-10 SG SG2012000964A patent/SG177535A1/en unknown
  • 2010-07-10 CN CN201310670649.XA patent/CN103848808B/zh not_active Expired - Fee Related
  • 2010-07-10 CA CA2768788A patent/CA2768788C/en not_active Expired - Fee Related
  • 2010-07-10 MA MA34562A patent/MA33452B1/fr unknown
  • 2010-07-10 KR KR1020127001737A patent/KR101763437B1/ko not_active Expired - Fee Related
  • 2010-07-10 MX MX2012001063A patent/MX2012001063A/es active IP Right Grant
  • 2010-07-10 PE PE2012000092A patent/PE20120573A1/es not_active Application Discontinuation
  • 2010-07-10 CN CN201080031572.6A patent/CN102471246B/zh not_active Expired - Fee Related
  • 2010-07-10 WO PCT/EP2010/004222 patent/WO2011009541A1/en not_active Ceased
  • 2010-07-10 AU AU2010275780A patent/AU2010275780B2/en not_active Ceased
  • 2010-07-22 UY UY0001032800A patent/UY32800A/es not_active Application Discontinuation
  • 2010-07-23 AR ARP100102678A patent/AR079183A1/es unknown
• 2012
  • 2012-01-01 IL IL217312A patent/IL217312A/en not_active IP Right Cessation
  • 2012-01-19 TN TNP2012000027A patent/TN2012000027A1/en unknown
  • 2012-01-23 CR CR20120044A patent/CR20120044A/es unknown
  • 2012-01-24 CL CL2012000192A patent/CL2012000192A1/es unknown
  • 2012-01-24 CO CO12010431A patent/CO6491075A2/es active IP Right Grant
  • 2012-01-24 DO DO2012000017A patent/DOP2012000017A/es unknown
  • 2012-01-24 MX MX2014000732A patent/MX344965B/es unknown
  • 2012-01-24 GT GT201200017A patent/GT201200017A/es unknown
  • 2012-01-24 EC EC2012011621A patent/ECSP12011621A/es unknown
  • 2012-01-24 HN HN2012000142A patent/HN2012000142A/es unknown
• 2013
  • 2013-04-23 US US13/868,621 patent/US8884058B2/en not_active Expired - Fee Related
• 2014
  • 2014-01-16 PH PH12014500158A patent/PH12014500158B1/en unknown
  • 2014-08-25 US US14/467,424 patent/US9296686B2/en not_active Expired - Fee Related

Patent Citations (2)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events